Navigation Links
GNS Healthcare Collaborates with NCI in New Approach to Lung Cancer; Supercomputer Analysis to Aid in Matching Targeted Drugs to Patients
Date:7/12/2011

CAMBRIDGE, Mass., July 12, 2011 /PRNewswire/ -- GNS Healthcare, Inc. (GNS) is collaborating with the National Cancer Institute (NCI) to accelerate lung cancer research with a supercomputing platform that can rapidly uncover cause-and-effect mechanisms hidden in huge data sets assembled from imaging, genetics, pathology, and other areas. The results could help predict which patients will respond to a given treatment.

GNS will analyze NCI data from the laboratory of Terry van Dyke, Ph.D., Director of the Center for Advanced Preclinical Research (CAPR) at NCI. These data were generated from genetically modified mouse models of non-small cell lung cancer (NSCLC).

This collaboration will utilize GNS's supercomputer-driven REFS(TM) platform to build computer models of NSCLC in a hypothesis-free, unbiased manner that will be simulated to identify key molecular mechanisms of NSCLC.  The goal is to identify biomarkers and biological mechanisms that will lead to better matching of drugs to patients and new effective drugs in NSCLC.

"GNS is excited to be deploying our supercomputer-driven REFS(TM) platform to enable the maximal extraction of actionable knowledge from the rich lung cancer datasets generated by the NCI," said GNS Executive Vice President and Co-Founder Dr. Iya Khalil. "Combined with the expertise of our NCI colleagues in lung cancer biology and in designing powerful experiments to uncover its key mechanisms, we are creating the opportunity to provide better outcomes for lung cancer patients."

The data utilized in the collaboration will include data from the experimental assessment of transcriptomic and MRI data relating to NSCLC induction, regression and combination drug treatments.  Starting from this data, GNS will utilize the REFS(TM) platform to reverse-engineer network models from the data that connect drug doses to transcriptional and imaging measurement networks to endpoints. The results from millions of in silico simulations of these models will provide unique insights into the fundamental mechanisms of NSCLC and its response to drug treatments, enabling the development of more effective treatments for NSCLC.

The initial phase of this project is also intended to help GNS and NCI develop standards for the exchange of data to conduct future collaborations in other relevant mouse model systems.  From this starting point, the groups envision the possibility of a combined experimental and computational work flow aimed at rapidly enabling the generation of hypotheses, testing these hypothesis in silico and in vivo, generating new confirmatory data, and rapidly cycling back to additional computational modeling, with the goal of accelerating the conversion of knowledge into new clinical options for cancer patients.  

About REFS(TM)

REFS(TM) is comprised of integrated machine learning algorithms and software that extract "causal" relationships from complex, multi-dimensional data and enable the simulation of billions of "what if?" hypotheses to explore novel unseen conditions and predictions forward in time. This model-centric discovery and simulation approach represents a paradigm shift in data analysis, leapfrogging existing approaches such as high-dimensional pattern matching. REFS(TM) is licensed to GNS Healthcare from Via Science.

About GNS Healthcare, Inc.

GNS Healthcare (www.gnshealthcare.com), a subsidiary of Via Science, is a healthcare IT company that applies machine learning and simulation technology to optimize patient treatment in partnership with health insurance companies, pharmacy benefit managers, and pharmaceutical & biotech companies. GNS Healthcare is the leading "big data" healthcare analytics firm between drug makers and drug buyers, matching treatments to patients to deliver on the promise of "smart" medicine.

About the National Cancer Institute CAPR

The National Cancer Institute (NCI) leads the National Cancer Program and the National Institutes of Health's effort to dramatically reduce the burden of cancer and improve the lives of cancer patients and their families, through research into prevention and cancer biology, the development of new interventions, and the training and mentoring of new researchers.

The NCI Center for Advanced Preclinical Research (CAPR) is a national resource for the comprehensive preclinical testing of early-stage candidate drugs. The center is developing a comprehensive preclinical trial framework for evaluating the anti-tumor efficacy and selectivity, biodistribution, and metabolism of early-stage candidate drugs using genetically engineered mouse (GEM) models. Its mission is to facilitate the improvement of preclinical evaluation for effective cancer diagnosis and treatment.

Contact:
Thomas A. Neyarapally
GNS Healthcare
617-494-0492

This project is being partially funded with Federal funds from the National Cancer Institute, National Institutes of Health.  The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.


'/>"/>
SOURCE GNS Healthcare, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology news :

1. New Healthcare Franchise Opportunity Focuses on Treating Exploding Senior Population
2. Corning, GE Healthcare to receive Technical Achievement Award from Ceramic Society
3. Lexicon to Present Clinical Data for Diabetes Drug Candidate, LX4211, at Two Major Healthcare Conferences
4. Inventor honored for tech improving access to clean water, healthcare, and business development in India
5. The Full Yield, Inc. Launches Breakthrough Collaboration to Put Food Back at the Heart of Healthcare
6. TGen-Scottsdale Healthcare researchers make breakthrough in lung cancer
7. GE Healthcare to evaluate and develop novel imaging technology
8. Scott & White Healthcare researcher finds success with new anti-cancer drug
9. Scott & White Healthcare researcher finds success with new anti-cancer drug
10. GE Healthcare President & CEO, Mark Vachon, to Present at BioConference Live
11. TGen Clinical Research Services at Scottsdale Healthcare and Mayo Clinic study new cancer drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/14/2016)... Calif. , Nov. 14, 2016 /PRNewswire/ ... biometric identification market, Frost & Sullivan recognizes ... & Sullivan Award for Visionary Innovation Leadership. ... in the biometric identification market by pioneering ... verification solution for instant, seamless, and non-invasive ...
(Date:6/22/2016)... ANGELES , June 22, 2016 /PRNewswire/ ... identity management and verification solutions, has partnered ... edge software solutions for Visitor Management, Self-Service ... provides products that add functional enhancements ... partnership provides corporations and venues with an ...
(Date:6/20/2016)... -- Securus Technologies, a leading provider of civil ... investigation, corrections and monitoring announced that after exhaustive ... the final acceptance by all three (3) Department ... (MAS) installed. Furthermore, Securus will have contracts for ... October, 2016. MAS distinguishes between legitimate wireless device ...
Breaking Biology News(10 mins):
(Date:11/30/2016)... 2016  The Allen Institute for Cell Science ... publicly available collection of gene edited, fluorescently tagged ... cellular structures with unprecedented clarity. Distributed through the ... are a crucial first step toward visualizing the ... makes human cells healthy and what goes wrong ...
(Date:11/30/2016)... Nov. 30, 2016  Tempus, a technology company ... and Penn,s Abramson Cancer Center have partnered to ... response to immunotherapy treatment based on next generation ... part of a research collaboration, Tempus will provide ... cancer patient data to Penn. Utilizing next-generation sequencing, ...
(Date:11/30/2016)... 2016   Merck , ein führendes ... einer Reihe von Vereinbarungen mit Evotec AG ... Screeningleistungen für Mercks Palette genetischer Reagenzien wie ... diese Bibliotheken in Kombination mit Evotecs Expertise ... zur Ermittlung und Erforschung neuer Arzneimitteltargets.    ...
(Date:11/30/2016)... 30, 2016   Merck , a leading science ... into a set of agreements with Evotec AG, whereby ... of genetic reagents such as CRISPR and shRNA libraries. ... offers an accelerated pathway to explore and identify new ... identification of new targets, a process that can be ...
Breaking Biology Technology: